Uzbek-Chinese vaccine is approved for emergency use in China
The Ministry of Innovative Development of the Republic of Uzbekistan reports that a recombinant vaccine (CHO cells) against the new form of coronavirus has been approved in China for emergency use.
The vaccine was developed by the Institute of Microbiology of the Chinese Academy of Sciences and Anhui Zhifei Longcom Biopharmaceutical Co. Ltd.
Vaccine research began in early 2020 and the results were published in the international journal Cell. Phase I and II vaccine trials were completed in October 2020.
It is the fourth coronavirus vaccine developed and approved in China for emergency use.
In November 2020, Phase III clinical trials of the vaccine began in China, Uzbekistan, Pakistan, Ecuador and Indonesia. Phase III clinical trials were successful and no serious side effects of the vaccine were detected in Uzbekistan, which was one of the first countries to start the research.
Phase III clinical trials of a recombinant vaccine produced by the Chinese company Anhui Zhifei Loncom Biofharmaceutical are carried out by the Center for Advanced Technologies under the Ministry of Innovative Development of the Republic of Uzbekistan and the Research Institute of Virology of the Ministry of Health.
China announced the acceptance of Uzbekistan as a co-author for its active participation in the research of this vaccine. The vaccine is registered in Uzbekistan under the name ZF-UZ-VAC 2001.